Medical Network News, September 29: Since 2020, affected by the special period, the development potential of the domestic medical device industry has been continuously highlighted, and the pace of import substitution has accelerated. The "Overview of the Development of Medical Device Trade in the First Half of 2020" shows that my country's medical device import and export trade volume was 26.641 billion US dollars in the first half of 2020, a year-on-year increase of 2.98%. Among them, the export value was 16.313 billion US dollars, a year-on-year increase of 22.46%; the import value was 10.328 billion US dollars, a year-on-year decrease of 20.79%. In the first half of the year, my country's medical equipment imports showed a negative growth, which also means that domestic medical equipment may usher in the opportunity of "curving overtaking", and there is huge room for import substitution.

Previously, the industry analyzed the market situation of domestic medical devices in the second half of the year, and believed that the demand for medical devices in foreign markets was still huge in the second half of the year, and most domestic listed medical device companies were on the list of the Ministry of Commerce. The equipment industry brings opportunities.

　　 Judging from the performance of domestic medical devices in the first half of this year, the leading company Mindray Medical surpassed the leading companies in chemical pharmaceuticals and traditional Chinese medicine for the first time, with a year-on-year increase of 45.78% in net profit and continued improvement in brand influence. In addition, as of now, 346 listed A-share pharmaceutical and biological companies have released annual reports for the first half of 2020. Among the top 20, in addition to Mindray Medical, there are five medical device companies that have increased their net profit attributable to parent companies by more than 1,000%, including Shengxiang Biological, Intech Medical, Kangtai Medical, Zhende Medical, Oriental Biological.

　　 At present, although the country also promotes centralized procurement in the medical device industry, it mainly targets high-value consumables. The industry expects this to have a greater impact on multinational companies. In the recent bid-winning catalogs for the purchase of high-value medical consumables in various places, domestically-made devices account for the majority. Many top three hospitals clearly do not accept bids for imported products in their bidding announcements, or indicate that product categories that are not specifically specified do not accept imported products.

　　 my country has successively carried out the procurement of high-value medical consumables in various places in order to reduce the burden of patients' expenses. Among them, orthopedic consumables have been issued and implemented in 14 provinces, ophthalmic consumables have been issued but not implemented in 8 provinces, and interventional coronary stents are the first batch of varieties to be purchased nationwide.

　　 Public data shows that the market size of high-value medical consumables in my country is 104.6 billion yuan, of which vascular intervention and orthopedic implants are 38.9 billion yuan and 26.2 billion yuan respectively.

　　 The industry pointed out that in fact, the price gap between domestic and imported coronary stents is already very large. The ex-factory price of domestic stents differs by 9 times from the price of entering hospitals, while the ex-factory price of imported stents differs by 6.5 times from entering domestic hospitals. At present, the technology of domestic and imported products in the field of coronary stents is quite different. It is expected that with the advancement of the collection of high-value medical consumables, domestic coronary stents can be replaced by imports.

On the whole, my country’s low- and medium-end medical device products have long been recognized by the international market, and many breakthroughs have been achieved in the high-end field. For example, most of the medical devices and consumables in the orthopedics field have been in line with high-end imported products in terms of quality and performance. .

In the long run, under the influence of factors such as the continuous escalation of medical consumption, the gradual relaxation of registration conditions, the accelerating approval process, the increasingly reasonable price level, the expansion of medical insurance reimbursement, and the increase in product admission opportunities, the medical device industry will be forced to shift from imitation Transition to innovation, the pace of import substitution of domestic high-end medical devices may accelerate, and higher requirements will be put forward for the technological research and development and iterative upgrading of medical devices.